Kasumi-1 (ATCC® CRL-2724)

Organism: Homo sapiens, human  /  Cell Type: myeloblast  /  Tissue: peripheral blood  /  Disease: acute myeloblastic leukemia

Organism Homo sapiens, human
Tissue peripheral blood
Cell Type myeloblast
Product Format frozen
Morphology myeloblast
Culture Properties suspension
Biosafety Level 1
Disease acute myeloblastic leukemia
Age 7 years
Gender male
Ethnicity Japanese
Storage Conditions liquid nitrogen vapor phase
Karyotype t(8:21) (q22;q22)
Images
Derivation
The cell line was established from the peripheral blood of an acute myeloid leukemia (AML) patient.
Clinical Data
7 yrs juvenile
Japanese
male
­
Comments

This is a leukemic cell line with an 8;21 chromosome translocation. This translocation juxtaposes the AML1 with ETO (or MTG8) gene, giving rise to the fusion gene AML1-ETO (also known as AML1-MTG or RUNX1-CBF2T1), hence the cells produce chimeric AML1-ETO protein. This protein down-regulates CEBPA mRNA, protein and DNA binding activity, which is crucial for the differentiation of granulocytes.

The cells are positive for myeloperoxidase showing a morphology of myeloid maturation.

In proliferation assay the cells in culture showed response to interleukin-3 (IL-3), IL-6, granulocyte colony-stimulating factor (G-CSF), and granulocytemacrophage CSF (GM-CSF), but not to IL-1 or IL-5.

Neither granulocytic nor eosinophilic maturation was observed in the in vitro liquid culture by the addition of dimethyl sulfoxide, G-CSF, or IL-5, respectively. Induction of macrophagelike cells was seen by the addition of phorbol ester. Proliferation is inhibited by 1,25S-(OH)2-16,23-diene-26-F3-10-nor D3.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Subculturing
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 x 105 viable cells/mL.

Interval: Maintain cell density between 3 x 105 and 3 x 106 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)

Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
STR Profile
D5S818: 9,11
D13S317: 11,13
D7S820: 8,11
D16S539: 9,12
vWA: 14
THO1: 6,9
Amelogenin: X
TPOX: 8,9
CSF1PO: 10,12
Name of Depositor H Asou
Year of Origin November 8, 1989
References

Tashiro S, et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 77: 2031-2036, 1991. PubMed: 2018839

Miyoshi H, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12: 2715-2721, 1993. PubMed: 8334990

Miyoshi H, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA 88: 10431-10434, 1991. PubMed: 1720541

Asou H, et al. 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92: 2441-2449, 1998. PubMed: 9746784

Kozu T, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 82: 1270-1276, 1993. PubMed: 8353289

Pabst T, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 7: 444-451, 2001. PubMed: 11283671

Basic Documentation
Other Documentation
References

Tashiro S, et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 77: 2031-2036, 1991. PubMed: 2018839

Miyoshi H, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12: 2715-2721, 1993. PubMed: 8334990

Miyoshi H, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA 88: 10431-10434, 1991. PubMed: 1720541

Asou H, et al. 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92: 2441-2449, 1998. PubMed: 9746784

Kozu T, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 82: 1270-1276, 1993. PubMed: 8353289

Pabst T, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 7: 444-451, 2001. PubMed: 11283671